Search results for "ulcer."

showing 10 items of 519 documents

Antibodies to Cathepsin G in Crohn's disease

1992

. Antibodies directed against antigens in human neutrophils have proved to be of great diagnostic value in certain systemic vasculitides. Recent reports have focused the attention on these antigens as targets of antibodies in sera of patients with inflammatory bowel disease. We investigated the sera drawn from 60 patients suffering from biopsy proven Crohn's disease and 15 patients with active ulcerative colitis. Using sensitive enzyme-linked immunosorbent assays with purified antigens and Western blotting the following antibodies could be demonstrated: cathepsin G (cat-G) antibodies IgG 38.3%, IgM 13.3%, IgA 23.3% and antibodies against human leucocyte elastase (HLE) IgG, IgA, IgM 3.3%. Lo…

AdultMaleCathepsin GAdolescentAnti-nuclear antibodyNeutrophilsBlotting WesternClinical BiochemistryImmunoglobulinsEnzyme-Linked Immunosorbent AssayCathepsin GBiochemistryInflammatory bowel diseasechemistry.chemical_compoundCrohn DiseaseAntigenProteinase 3HumansMedicineChildAgedAutoantibodiesCrohn's diseasePancreatic Elastasebiologybusiness.industrySerine EndopeptidasesGeneral MedicineMiddle Agedmedicine.diseaseCathepsinsUlcerative colitischemistryImmunologybiology.proteinElectrophoresis Polyacrylamide GelFemaleAntibodybusinessEuropean Journal of Clinical Investigation
researchProduct

Combined Therapy with Azathioprine, Prednisolone, and Ursodiol in Patients with Primary Sclerosing Cholangitis: A Case Series

1999

No established medical therapy alters the progressive course of primary sclerosing cholangitis.To explore the potential usefulness of combined therapy with azathioprine, steroids and ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis.Case series.University hospital in Mainz, Germany.15 patients with primary sclerosing cholangitis.Azathioprine (1 to 1.5 mg/kg of body weight per day), prednisolone (1 mg/kg per day initially, tapering to 5 to 10 mg per day) and UDCA (500 to 750 mg per day).Clinical and laboratory evaluation, liver biopsy, and endoscopic retrograde cholangiography (a30% change in stenosis was considered significant).After a median observation period of 41 months (ran…

AdultMaleCholagogues and Cholereticsmedicine.medical_specialtyPrednisolonemedicine.medical_treatmentCholangitis SclerosingPilot ProjectsAzathioprineAutoimmune hepatitisGastroenterologyInflammatory bowel diseasePrimary sclerosing cholangitisInternal medicineAzathioprineInternal MedicinemedicineHumansChemotherapybusiness.industryUrsodeoxycholic AcidGeneral Medicinemedicine.diseaseUlcerative colitisUrsodeoxycholic acidSurgeryRadiographyLiverPrednisoloneDrug Therapy CombinationFemalebusinessImmunosuppressive Agentsmedicine.drugAnnals of Internal Medicine
researchProduct

Hsp60 and Hsp10 increase in colon mucosa of Crohn's disease and ulcerative colitis.

2010

The purpose of this work was to determine in colon mucosa of Crohn’s disease (CD) and ulcerative colitis (UC) in relapse: a) the levels of the chaperonins Hsp60 and Hsp10; b) the quantity of inflammatory cells; and c) if the levels of chaperonins parallel those of inflammation cells. Twenty cases of CD and UC and twenty normal controls (NC) were studied using immunohistochemistry, Western blotting and immunofluorescence. Immunohistochemically, Hsp60 and Hsp10 were increased in both inflammatory bowel diseases (IBD) compared to NC. These results were confirmed by Western blotting. Hsp60 and Hsp10 occurred in the cytoplasm of epithelial cells in CD and UC but not in NC. Hsp60 and Hsp10 co-loc…

AdultMaleColonConnective tissueInflammationBiologyBiochemistryImmune systemSettore MED/38 - Pediatria Generale E SpecialisticaCrohn DiseaseIntestinal mucosaChaperonin 10LeukocytesmedicineHumansIntestinal MucosaColitisIBD HSP 60 HSP 10AgedOriginal PaperLamina propriaCrohn's diseaseEpithelial CellsChaperonin 60Cell BiologyMiddle Agedmedicine.diseaseUlcerative colitismedicine.anatomical_structureImmunologyColitis UlcerativeFemalemedicine.symptom
researchProduct

The use of proton pump inhibitors in an Italian hospital: focus on oncologic and critical non-ICU patients

2015

Background Proton pump inhibitors (PPIs) are among the most misused drugs both at the community and hospital level. Recently, possible risks have been underscored, suggesting the importance of limiting PPI use to proven indications. Objective To survey the appropriateness of PPI use in a University hospital in Italy. Setting Azienda Ospedaliera Universitaria Policlinico ‘P. Giaccone’, in Palermo, Italy. Method A one day-observational study, reviewing patients’ medical records to identify treatments with PPIs and the indications for their use. After discharge, a subgroup of the cohort was followed up to assess the continuation of therapy at home. Appropriateness was evaluated according to th…

AdultMaleDrug UtilizationDrugmedicine.medical_specialtyIcu patientsmedia_common.quotation_subjectPharmaceutical ScienceInappropriate PrescribingPharmacyPharmacyProton pump inhibitorToxicologyHospitals UniversityHospitalmedicineDrug utilizationHumansPharmacology (medical)Stomach UlcerMedical prescriptionIntensive care medicineAgedmedia_commonPharmacologybusiness.industryMedical recordStress ulcerProton Pump InhibitorsMiddle Agedmedicine.diseasePatient DischargeHospitalizationTherapeutic appropriateneItalyPractice Guidelines as TopicCohortSettore BIO/14 - FarmacologiaFemaleGuideline Adherencebusiness
researchProduct

A randomized trial assessing the effectiveness of different concentrations of isotretinoin in the management of lichen planus

2004

The aim of our 10-year study was to test the effectiveness of topical therapy based on 0. 18% isotretinoin, comparing it with that most frequently used, i.e. at 0.05% concentration. Seventy patients with an established diagnosis of oral lichen planus were involved in the study. The patients were randomly divided into two groups, and the drug was administered topically at 0.05% and 0. 18% concentrations. The drug at the higher concentration, according to the same protocol, was administered to the patients who did not benefit from the therapy at the lower concentration. None of the cases of reticular lichen planus showed clinical or histological improvement. In contrast, the atrophic-erosive …

AdultMaleDrugmedicine.medical_specialtyHot TemperatureRandomizationAdministration Topicalmedicine.medical_treatmentmedia_common.quotation_subjectSensationPainoral lichen planus isotretinoinlaw.inventionRandomized controlled trialRecurrencelawOral and maxillofacial pathologyHumansMedicineIsotretinoinOral UlcerIsotretinoinAgedmedia_commonChemotherapybusiness.industrySmokingMiddle Agedmedicine.diseaseDermatologyClinical trialstomatognathic diseasesTreatment OutcomeOtorhinolaryngologyFemaleSurgeryOral lichen planusDermatologic AgentsOral SurgerybusinessFollow-Up StudiesLichen Planus Oralmedicine.drug
researchProduct

Treatment of Ulcerative Colitis with Olsalazine and Sulphasalazine: Efficacy and Side-Effects

1988

The effects of olsalazine were studied mainly in patients with ulcerative colitis who were intolerant to sulphasalazine, and for relapse prevention. A crossover design with sulphasalazine, 3 g/day, and olsalazine, 1.5 g/day, was applied to compare the side-effects of each drug and to evaluate their therapeutic efficacy. A total of 41 patients with mild or moderately severe left-sided colitis or proctitis were assigned to a randomized treatment schedule. Olsalazine and sulphasalazine were similar in their therapeutic efficacy. Twelve patients complained of adverse effects while on sulphasalazine and 4 patients during olsalazine treatment (p less than 0.05). It is concluded that olsalazine is…

AdultMaleDrugmedicine.medical_specialtymedia_common.quotation_subjectRelapse preventionGastroenterologyRandom AllocationDouble-Blind MethodInternal medicinemedicineHumansProctitisColitisAdverse effectProctitismedia_commonOlsalazineClinical Trials as Topicbusiness.industryGastroenterologymedicine.diseaseUlcerative colitisCrossover studySulfasalazineAminosalicylic AcidsColitis UlcerativeFemalebusinessmedicine.drugScandinavian Journal of Gastroenterology
researchProduct

IRF4 regulates IL-17A promoter activity and controls RORγt-dependent Th17 colitis in vivo

2011

The transcription factor IRF4 is involved in several T-cell-dependent chronic inflammatory diseases. To elucidate the mechanisms for pathological cytokine production in colitis, we addressed the role of the IRF transcription factors in human inflammatory bowel disease (IBD) and experimental colitis.IRF levels and cytokine production in IBD patients were studied as well as the effects of IRF4 deficiency in experimental colitis.In contrast to IRF1, IRF5, and IRF8, IRF4 expression in IBD was augmented in the presence of active inflammation. Furthermore, IRF4 levels significantly correlated with IL-6 and IL-17 mRNA expression and to a lesser extent with IL-22 mRNA expression in IBD. To further …

AdultMaleElectrophoretic Mobility Shift AssayInflammatory bowel diseasePolymerase Chain Reaction03 medical and health sciencesMice0302 clinical medicineCrohn DiseaseRAR-related orphan receptor gammaImmunology and AllergyMedicineAnimalsHumansColitisInterleukin 6Promoter Regions GeneticTranscription factor030304 developmental biology0303 health sciencesCrohn's diseasebiologybusiness.industryInterleukin-6Interleukin-17GastroenterologyMiddle AgedNuclear Receptor Subfamily 1 Group F Member 3medicine.diseaseColitisInflammatory Bowel Diseasesdigestive system diseases3. Good health030220 oncology & carcinogenesisImmunologyInterferon Regulatory Factorsbiology.proteinTh17 CellsColitis UlcerativeFemaleInterleukin 17businessInterferon regulatory factors
researchProduct

Is Epstein-Barr virus infection associated with the pathogenesis of microscopic colitis?

2017

Abstract Background Epstein-Barr virus (EBV) has been associated with inflammation in the colon, particularly in patients with inflammatory bowel disease (IBD). Even if a relevant plasmocytosis, similar to IBD, is present in microscopic colitis (MC), the frequency of EBV infection in this setting is unknown. Objectives We aimed to compare the frequency of colonic EBV infection in patients with MC, ulcerative colitis (UC), and irritable bowel syndrome (IBS). Study design The frequency of colonic EBV infection in biopsies of 30 patients with MC, 30 patients with UC, and 30 controls with IBS was retrospectively assessed. PCR was performed to detect viral EBV DNA in colonic biopsies. In situ hy…

AdultMaleEpstein-Barr Virus InfectionsHerpesvirus 4 HumanColonBiopsymedicine.disease_causeInflammatory bowel diseasePolymerase Chain ReactionPathogenesisIrritable Bowel Syndrome03 medical and health sciences0302 clinical medicineMicroscopic colitishemic and lymphatic diseasesVirologyBiopsymedicineHumansEpstein–Barr virus infectionIrritable bowel syndromeIn Situ HybridizationAgedRetrospective Studiesmedicine.diagnostic_testbusiness.industryMiddle Agedmedicine.diseaseUlcerative colitisEpstein–Barr virusdigestive system diseasesColitis MicroscopicInfectious Diseases030220 oncology & carcinogenesisImmunologyDNA ViralRNA Viral030211 gastroenterology & hepatologyColitis UlcerativeFemalebusinessJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology
researchProduct

Impaired Health-Related Quality of Life in Inflammatory Bowel Diseases Psychosocial Impact and Coping Styles in a National German Sample

2001

The purpose of this study is to give a detailed survey of the disease-specific and generic quality of life (HRQOL) of adult patients suffering from inflammatory bowel disease (IBD) in Germany.1322 patients suffering from IBD were examined in a cross-sectional study. A questionnaire assessing disease-specific and generic quality of life, coping, and hopelessness was sent to members of the German Crohn/Colitis association.Compared to the general population, the generic HRQOL in IBD patients is significantly reduced. Active coping has a negative influence on patients' generic physical HRQOL during an active phase (beta = -0.31), while this association is not present in the case of patients in …

AdultMaleGerontologymedicine.medical_specialtyCoping (psychology)Cross-sectional studySeverity of Illness IndexInflammatory bowel diseaseAge DistributionCrohn DiseaseGermanySickness Impact ProfileSurveys and QuestionnairesAdaptation PsychologicalEpidemiologymedicineHumansSex DistributionProbabilitybusiness.industryPublic healthGastroenterologyMiddle AgedInflammatory Bowel DiseasesPrognosismedicine.diseaseHealth SurveysUlcerative colitisdigestive system diseaseshumanitiesCross-Sectional StudiesPsychological well-beingMultivariate AnalysisLinear ModelsQuality of LifeColitis UlcerativeFemalebusinessPsychosocialClinical psychologyScandinavian Journal of Gastroenterology
researchProduct

Natural history of cytomegalovirus infection in a series of patients diagnosed with moderate-severe ulcerative colitis

2011

AIM: To evaluate the natural history of human cytomegalovirus (HCMV) infection in a series of 28 ulcerative colitis patients in whom the search for HCMV was positive. METHODS: A series of 85 patients with moderate-severe ulcerative colitis flare-up were evaluated for a HCMV search by performing a haematoxylin and eosin stain, immunohistochemical assay and nested polymerase chain reaction on rectal biopsies. Among 85 screened patients (19 of whom were steroid resistant/dependant), 28 were positive for HCMV; after remission the patients were followed up clinically and histologically. RESULTS: Among the 22 patients with complete follow-up, in 8 (36%) patients HCMV-DNA persisted in the intestin…

AdultMaleHuman cytomegalovirusmedicine.medical_specialtyBrief ArticlevirusesCongenital cytomegalovirus infectionCytomegalovirusGastroenterologyRecurrenceInternal medicinemedicineHumansProspective StudiesColitisProspective cohort studyAntigens ViralAcute colitisAgedbusiness.industryRemission InductionGastroenterologyvirus diseasesGeneral MedicinePouchitisMiddle Agedbiochemical phenomena metabolism and nutritionmedicine.diseaseUlcerative colitisCytomegalovirus InfectionsDNA ViralImmunologyColitis UlcerativeFemalebusinessNested polymerase chain reactionWorld Journal of Gastroenterology
researchProduct